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Using an infectious cDNA clone we engineered seven mutations in the putative heparan sulfate- and
receptor-binding motifs of the envelope protein of dengue virus serotype 2, strain 16681. Four mutant
viruses, KK122/123EE, E202K, G304K, and KKK305/307/310EEE, were recovered following transfection of
C6/36 cells. A ﬁfth mutant, KK291/295EE, was recovered from C6/36 cells with a compensatory E295V
mutation. All mutants grew in and mediated fusion of virus-infected C6/36 cells, but three of the
mutants, KK122/123EE, E202K, G304K, did not grow in Vero cells without further modiﬁcation. Two Vero
cell lethal mutants, KK291/295EV and KKK307/307/310EEE, failed to replicate in DC-SIGN-transformed
Raji cells and did not react with monoclonal antibodies known to block DENV attachment to Vero cells.
Additionally, both mutants were unable to initiate negative-strand vRNA synthesis in Vero cells by 72 h
post-infection, suggesting that the replication block occurred prior to virus-mediated membrane fusion.
Published by Elsevier Inc.Introduction
Dengue virus (DENV), a member of Flaviviridae family, contains a
positive-strand (þ) RNA genome and three structural proteins:
envelope (E), membrane (M), and capsid (C). The E protein
assembles in the virion envelope as homodimer rafts, and mediates
viral entry into cells via attachment, endocytosis, and fusion with
endosomal membranes—delivering the capsid into the cell cyto-
plasm. The E protein folds into three major domains. Domain I (DI)
is the central domain containing the protein “hinge” responsible for
the low pH-catalyzed conformational change from homodimers to
fusion-competent homotrimers. Domain II (DII) is the dimerization
domain containing the fusion peptide at its tip. Domain III (DIII) is
an immunoglobulin-like structure suggested to mediate binding of
virus to cellular receptors (Kuhn et al., 2002; Modis et al., 2003,
2005; Mukhopadhyay et al., 2005; Nayak et al., 2009).
DENV replication begins with the attachment of virus to
cellular receptors. It is now well established that cell surfaceInc.
.com (J.T. Roehrig).
treet, Liverpool L69 3 GA, UK.glycosaminoglycans (GAGs), such as heparan sulfate (HS), can facil-
itate ﬂaviviral attachment to cultured mammalian cells (Chen et al.,
1997; Germi et al., 2002; Hilgard and Stockert, 2000; Hung et al.,
1999). After solving the crystal structures of DENV2 and DENV3 E
proteins, Modis et al. (2003, 2005) suggested that three clusters of
positively charged amino acids (AAs) on E protein homodimer
surface might be involved in HS binding. Cluster 1, located in DI,
consists of R188, H282, K284, R286, K288, K291, and K295 (based on
DENV2 E protein residue numbers) and all of these are conserved as
basic residues among all 4 DENV serotypes and the Japanese
encephalitis virus (JEV) complex, including West Nile virus (WNV),
Murray Valley encephalitis virus (MVEV), and St. Louis encephalitis
virus (SLEV). Cluster 2, located in the middle of DII near the dimer
interface, includes K58, K64, K89, K122, K123, and K128 for DENV2.
Unlike cluster 1, cluster 2 is less conserved among the DENV or JEV
serocomplex viruses, and DENV2 contains more basic residues in this
cluster than other DENV serotypes. The moderately variable cluster
3 resides (K305. K307, K310) on or near the DIII lateral ridge,
including AAs important for both binding of virus-neutralizing anti-
body and interacting with cellular receptors (Diamond et al., 2008;
Sukupolvi-Petty et al., 2007).
Because GAGs are associated with the surfaces of many
cultured mammalian cells, cell-speciﬁc ﬂaviviral attachment – if
Fig. 1. Locations of HS-binding amino acid residues and mutations introduced in DENV2 E protein homodimers. Panel A: Location of possible HS-binding residues in
the three potential binding clusters (Modis et al., 2003). Colors indicate locations in DI (red), DII (yellow) or DIII (blue). Panel B: backbone depiction of one monomer
identiﬁes locations of all mutations discussed. The DIII-FG (VEPG) loop mutants (dark pink), fusion peptide mutants (orange), and hinge region mutants (red, green, purple,
and cyan) and have been previously described (Huang et al., 2010). Heparan sulfate-binding and DIII mutants (yellow, light pink, gray, and blue) and the G304K
compensatory mutation G330D (black) described in this paper are also depicted. The second glycoprotein monomer is shown in a space-ﬁlling model to illustrate residue
surface accessibility. The inset shows the conﬁguration of homodimers in the surface of the virion (Kuhn et al., 2002). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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Cell-speciﬁc interactions that result in differential DENV tissue-
tropisms in vivo probably involve other plasma membrane recep-
tors and potentially other E protein AAs. Several candidate cell
membrane proteins have been shown to bind DENV in vitro but all
are still poorly characterized (Martinez-Barragan and del Angel,
2001; Ramos-Castaneda et al., 1997). For example, it has been
suggested that different cell surface proteins might be responsible
for DENV binding to cultured monkey kidney cells (Vero) versus
human hepatoma cells (HepG2) (Marianneau et al., 1996). Several
size classes of mosquito cell (C6/36) membrane proteins appear to
bind DENV, but these proteins also remain uncharacterized
(Munoz et al., 1998; Salas-Benito and del Angel, 1997).
One surface protein, dendritic cell-speciﬁc intercellular adhe-
sion molecule-3-grabbing non-integrin (DC-SIGN), has been well-
studied as a ﬂavivirus attachment protein (Boonnak et al., 2008;
Davis et al., 2006a, 2006b). DC-SIGN binds to virion proteins
containing mannose glycans, and appears to be involved in DENV
infection of primary DCs or DC-SIGN-expressing transformed cell
lines—primarily through the carbohydrate moiety at the N67
glycosylation motif of the E protein (Pokidysheva et al., 2006).
Since oligosaccharides on mosquito cell-derived DENVs also con-
tain high mannose glycans, attachment to DCs via DC-SIGN may be
an important ﬁrst step following mosquito-bite transmission of
virus to humans (Hacker et al., 2009; Hsieh and Robbins, 1984).
The region of the E protein that might bind to cell-speciﬁc
receptors remains controversial, partly because the virion surfaceglycoprotein contains no well-deﬁned spike structures common to
other enveloped viruses (Kuhn et al., 2002; Mukhopadhyay et al.,
2003, 2006; Pletnev et al., 2001; Zhang et al., 2002). DIII was ﬁrst
hypothesized to contain the primary receptor-binding motif
because DIII-reactive neutralizing monoclonal antibodies (MAbs),
and to a lesser extent DI-reactive MAbs were most effective in
blocking DENV attachment to and infection of Vero cells (Crill and
Roehrig, 2001). MAbs against DII epitopes had measurable, but
lower, blocking activity. Several other reports also suggest that DIII
binds cellular receptors (Gromowski and Barrett, 2007; Modis
et al., 2003, 2005; Roehrig et al., 1998; Sukupolvi-Petty et al., 2007;
Thullier et al., 2001; Volk et al., 2007). Several AA changes in DIII
result in phenotypic changes usually associated with viral attach-
ment, e.g., host range, tissue tropism, or virulence, and DIII also
contains the most effective virus neutralization sites (Jennings
et al., 1994; Modis et al., 2005; Rey et al., 1995; Roehrig, 2003;
Roehrig et al., 1998). For WNV, DII also elicits effective neutralizing
antibodies in humans (Vogt et al., 2009).
Hung et al., demonstrated that soluble heparin blocked binding
of recombinant DIII (EIII) of DENV2 E-protein to BHK-21 cells, but
not to C6/36 cells(Hung et al., 2004). They also demonstrated that
a peptide representing AAs 380–389 of DIII (containing the DIII-FG
loop) inhibited binding of EIII to C6/36 but not BHK21 cells. These
results suggested that DENV binding to mammalian and mosquito
cells might be through different receptors. However, we have
previously determined that a mutant DENV2 with a deletion of the
DIII-FG loop (382VEPG385) was capable of infecting C6/36 cells,
Table 1
Amino acid variability in ﬂavivirus E proein HS-binding motifs.
Virusa HS-binding motif cluster 1b HS-binding motif cluster 2b,c HS-binding motif cluster 3b,c
1 2 2 2 2 2 2 1 1 1 2 3 3 3 3 3
8 8 8 8 8 9 9 5 6 8 2 2 2 0 0 0 0 0 1
8 2 4 6 8 1 5 8 4 9 2 3 8 2 3 4 5 7 0
DENV2 16681 R H K R R K K K K R K K K E T G K K K
DENV1 16007 R H K R K K K K K N V T K K T G S K K
DENV3 16562 R H K R K K K K K N L E K K L S S V K
DENV4 1036 R H K K R K K T S Q S G N K S G K S K
JEV
JaOArS982 R H K R K K K S S S T S R G T E K S K
WNV NY99 R H K R K K K S S A T T W G S K A K R
MVEV R H K R K K K N T N S N R G T E K T K
SLEV MSI7 R H K R K K K E T T K N K K D S A T K
YFV Asibi Q H K R K A K K V D A K F E T D K S K
TBEV
Neudoerﬂ A H T E G K K E K G K K H D D KT K T R
LGTV TP21 A H T E G K K E K G K K H D D KT K T R
POWV LB A H T D G K K E K N A K H D D KT K K R
a Accession numbers: U87411 (DENV2), AF180818 (DENV1), M18370 (JEV: Japanese encephalitis virus), AF196835 (WNV: West Nile virus), X03467 (MVEV: Murray Valley
encephalitis virus), AY289618 (SLEV: St. Louis encephalitis virus), AY640589 (YFV: yellow fever virus), U27495 (TBEV: tick-borne encephalitis virus), AF253419 (LGTV: Langat
virus), L06436 (POWV: Powassan virus).
b Amino acid positions of DENV2 E protein.
c Residues 202 and 303 are not basic residues in the HB-binding motif, but were targeted in this study to increase basic residues near the HB-binding cluster.
Table 2
Growth of DENV2-16681 E-protein mutant viruses in C636 and Vero cells and
resultant E-gene sequence of progeny virus.
Mutant virusesa Virus titer (TCID50/ml)b % Fusiond
C6/36 Vero
KK122/123EE 8.6370.2 Lethal (TS)c
└4K122E (V1) 9.1370.5 6.7570 85716
KKK122/123/128EEE Lethal Lethal N.d.
KRR284/286/288EEE Lethal Lethal N.d.
KK291/295EE Lethal Lethal
└4KK291/295EV (C0) 7.2570 Lethal (TS) 84710
KKK305/307/310EEE 7.2570 Lethal 9075
E202K 7.6370.2 Lethal
└4E202KþK122E (V1) n.d. 6.570 5475
G304K 9.3870.2 Lethal
└4G304KþG330D (V1) n.d. 6.2570 84714
30P-NBX (DENV2 16681) 9.6370 7.3870.2 100
a Bold-letters and arrows indicate amino acid changes associated with trans-
fection (0) or one passage (1) in Vero (V) or C6/36 (C) cells. Mutations were
identiﬁed by sequencing viral RNA from Vero cells at 12 days p.i.
b Peak infectious viral titer in growth curve (n¼2); n.d.¼not done.
c TS¼temperature sensitive: mutant virus was able to grow to similar titer as
the 30P-NBX in Vero cells at 28C without acquiring any compensatory muta-
tion.
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binding site for C6/36 cells (Erb et al., 2010). Three basic residues,
K305, K307, and K310, at a lateral ridge of DIII (DIII-A sheet in the
E-dimer structure) were also speculated to form a potential HS-
binding motif for DENV2 (Chen et al., 1997). A neutralizing epitope
has also been mapped to K307 (Lin et al., 1994), suggesting these
residues might be involved in viral attachment.
In an effort to gain a better understanding of mammalian cell
attachment and entry, we report here the use of site-directed
mutagenesis of a DENV2 infectious cDNA clone to introduce
mutations in the HS-binding clusters and the DIII lateral ridge of
the E protein. We evaluated the effects of these mutations on
growth in mosquito and mammalian cells, membrane fusion in
mosquito cells, attachment to Vero cells and DC-SIGN-expressing
Raji cells, and expression of MAb-deﬁned epitopes. Two Vero cell
lethal mutants, KK291/295EV and KKK307/307/310EEE, were
unable to initiate negative (−) sense viral (v)RNA synthesis in
Vero cells by 72 h post-infection (p.i.), or replicate in DC-SIGN Raji
cells, even though they were C6/36 cell-fusion competent, sug-
gesting that these mutations abrogate an early step in viral
replication, prior to virus-mediated endosomal membrane fusion.
Additionally, both of these mutant viruses failed to react with
MAbs shown previously to block DENV attachment to Vero cells.d Average percent fusion (7s,d,) of C6/36 cells fused with 30P-NBX positive
control (n¼2–5).Results
Mutant virus growth in different cell types
Location of the E protein HS-binding clusters is shown in
Fig. 1A. The ﬂavivirus AA variability of all clusters is shown in
Table 1. Based on these data, seven new DENV2 mutants targeting
the putative HS-binding motifs or DIII-A receptor binding motifs in
the viral E protein were prepared (Tables 1 and 2). Five mutations
were at basic AA residues, which were converted to acidic
residues, e.g., K/R-E. Residue 202, located in HS-binding cluster
2, is a basic K in DENV serotypes 1, 3, and 4, but it is acidic E for
DENV2 (Table 1). Therefore, an E202K mutation was made to
determine whether the additional basic residue for DENV2 in this
cluster is advantageous. Finally, a G304K mutation was made atthe DIII lateral ridge to increase the overall basic characteristics of
the DIII-A sheet.
From these 7 mutations, we recovered 5 viable mutant viruses
following transfection of C6/36 cells. Four mutants were as
designed: KK122/123EE, KKK305/307/310EEE, E202K, and G304K
(Table 2). Transfection of C6/36 cells with KK291/295EE-encoding
RNA resulted in isolation of a virus with KK291/295EV mutations.
The full-length viral genome sequence of each C6/36 working seed
virus was completed and with the exception of KK291/295EE-
KK291/295EV, only the introduced mutations were found.
Three of the mutant viruses were unable to grow in Vero cells
without subsequent modiﬁcation. Transfection of or a single
passage in Vero cells of the KK122/123EE mutant resulted in the
isolation of a K122E virus, where the engineered E123 mutation
reverted to K123. A single passage of the E202K mutant in Vero
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E202, or acquisition of a second compensating mutation, K122E, in
virus where the E202K mutation was conserved. A single passage
of G304K in Vero cells resulted in isolation of a mutant virus
containing an additional compensatory mutation, G330D. Most of
the reversions and/or compensatory substitutions were reprodu-
cible in 2–3 independent experiments to derive/amplify the
mutant viruses from Vero cells. The triple mutant, KKK305/307/
310EEE, and double mutant, KK291/295EV, were lethal for growth
in Vero cells. The KK291/295EV mutant was, however, able to
grow to very low titers in HepG2 (2.3log10 TCID50/ml) and K562
(2.4log10 TCID50/ml) cells. The KKK122/123/128EEE, KRR284/286/
288EEE, and KK291/295EE mutations were lethal in all cell types.
The locations of the HS binding and DIII mutations fromwhich live
virus were rescued are depicted in the E protein backbone diagram
in Fig. 1B. Since attachment of our previously published mutant
viruses is evaluated here, we have included the fusion peptide,
hinge region, and DIII-FG loop mutants in Fig. 1B (Butrapet et al.,
2011; Huang et al., 2010). Locations of all mutations are also
depicted on a space-ﬁlling monomer to show their surface
accessibility.
To characterize the phenotypes of these mutants, we prepared
growth curves in Vero and C6/36 cells based on genomic equiva-
lent titers by qRT-PCR (data not shown), and determined the peak
infectious virus titers between day 8 and 14 pi based on the TCID50
titers (Table 2). The clone-derived 30P-NBX virus was used as a
parental DENV2 16881 control throughout the experiments. We
used qRT-PCR to quantify the vRNA in culture medium (data not
shown) along with the TCID50 titer to monitor the infectivity of
mutant viruses. In C6/36 cells the KK291/295EV, KKK305/307/
310EEE, and E202K mutant titers were about 100-fold lower than
the 30P-NBX parental virus. The K122E and G304K mutant viruses
grew to similar levels as 30P-NBX. All viruses reached highest GE
titers by day 8 p.i. in C6/356 cells. Peak infectious titers (TCID50/
ml) were on day 12 pi (Table 2). Mutant viruses that contained
compensatory mutations permitting replication in Vero cells,
K122E, E202K/K122E, and G304K/G330D, had ~4- to10-fold reduc-
tions in titers as compared to 30P-NBX in Vero cells. The K122EFig. 2. Functional arrangement of E protein mutations yielding viable virus. The re
shown for virus-infected Vero (black bars) and C6/36 (white bars) cells (left y-axis). Also s
virus (100%) (gray bars) (right y-axis). Arrows identify mutants that do not grow in Ver
Growth and fusion data from the fusion loop, hinge region, and VEPG (DIII-FG) mutants
2010). Speciﬁc averages and standard deviation for the new HS mutants are given in Tamutant had similar growth kinetics (maximum GE titers between
day 8 and 12 p.i.) to wt virus and peak infectious titers on day 8 pi.
The peak infectious titers of K202K/L122E and G304K/G330D were
on day 12 pi (Table 2).
We also investigated the effect of temperature on growth of the
5 mutant viruses by comparing the growth in Vero cells at 37C and
28C at 4 days p.i. (data not shown). While all mutants grew to
some extent in Vero cells at 28C, only the KK122/123EE and
KK291/295EV mutants grew to the same level as 30P-NBX at 28C
while retaining the correct mutations in their progeny virus, thus
qualifying them as temperature sensitive (TS) in Vero cells
(Table 2).
Virus-mediated fusion of C6/36 cells
We have shown previously that mutation of the E protein
fusion peptide and hinge region results in viruses unable to grow
in Vero cells. This loss of growth in mammalian cells was
correlated with a defective virus-mediated fusion process in C6/
36 cells (Butrapet et al., 2011; Huang et al., 2010). Mutation of the
DIII-FG loop (VEPG382) did not result in a loss of fusion activity
(Erb et al., 2010). Fig. 2 compares all mutant viruses tested to date
for their growth in Vero and C6/36 cells, and their ability to
mediate membrane fusion in C6/36 cells. Table 2 gives speciﬁc
average values and standard deviations for only the new HS
mutants. For the new mutations reported in this study, the only
stable mutants, KK291/295EV and KKK305/307/310EEE, failed to
grow in Vero cells while maintaining fusion activity in C6/36 cells
(Fig. 2, arrows).
Epitope-binding analyses of mutant viruses
MAb-reacting epitopes of mutant E proteins were mapped by
IFA using acetone-ﬁxed, virus-infected C6/36 cells and a subset of
MAbs known to react with each domain of the E protein (Table 3).
Four-fold or greater differences in reactivity compared to 30P-NBX
virus were considered signiﬁcant changes in reactivity. No mutationslative growth of viruses (log TCID50/ml) measured at peak titer (12–14 days p.i.) is
hown is percent fusion of each mutant virus as compared to the 30P-NBX wild-type
o cells but are fusion competent in C6/36 cells. Bars represent mean values (n¼3).
have been published previously (Butrapet et al., 2011; Erb et al., 2010; Huang et al.,
ble 2.
Fig. 3. Epitope mapping of DENV2 E protein mutants using three anti-DENV mouse MAbs. Space-ﬁlling models of portions of DIII (left and center) and DI (right) of the
DENV E protein are shown with the MAb that binds to that epitope indicated above. The AAs known to be highly critical for MAb binding (red), and accessory binding AAs
(pink) in each epitope are indicated. The DENV epitope identiﬁed by each MAb is shown in parentheses (Roehrig et al., 1998). Reactivity with MAb of relevant mutant viruses
is shown in the lower tables. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 3
MAb epitope mapping of viruses containing mutant E-proteins determined by IFA end-point titration on virus-infected C6/36 cells.
Virus
E protein prM protein
Domain I Domain II Domain III
C1a A1 A4 B1 B2 B
1B4C-2b 6B6C-1 2H3 3H5 9A3D-8 1A1D-2 2H2
30PA-NBX 0.12c 0.12 0.63 0.31 1.88 0.24 0.12
K122/123E 0.12 0.12 0.63 0.63 1.88 0.24 0.12
K122E 0.12 0.12 0.63 0.63 1.88 0.24 0.12
KK291/295EV 0.47d 0.12 1.88 0.47 1.88 0.26 0.12
K305/307/310E 0.12 0.12 0.94 410 410 7.5 0.12
E202K 0.12 0.12 1.25 0.47 1.88 0.24 0.12
G304K 0.24 0.12 0.47 0.63 1.88 0.12 0.12
a Epitope (Roehrig et al., 1998).
b MAb (Roehrig et al., 1998).
c End-point MAb titer expressed in μg/ml, result is average from 3 to 4 experiments.
d Bold/underlined values indicate 4-fold or greater differences in end-point titers compared to wild-type virus, 30P-NBX.
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in DI lost reactivity with MAb 1B4C-2 (epitope C1). We showed
previously that the C1 epitope was also lost following a L135G
mutation (Butrapet et al., 2011). The DIII mutant KKK305/307/310EEE
lost reactivity with MAbs 3H5, 9A3D-8, and 1A1D-2. These MAbs
deﬁne DIII epitopes B1, B2, and B4, respectively. We showed
previously that all four VEPG mutants also lost reactivity with 3H5
(B1) (Erb et al., 2010). A summary of the MAb/mutant reactivity is
shown in Fig. 3, including locations of other AAs previously shown to
be involved in the binding of 1A1D-2 and 3H5 (Lok et al., 2008;
Sukupolvi-Petty et al., 2007). The last panel shows the locations of
K291 and K295 in DI, which are involved in the binding of 1B4C-2.
The location of L135 is not shown in the 1B4C-2 (C1) panel, although
the L135G mutation was previously shown to disrupt binding, since
it is located in the E protein hinge region and is not surface
accessible.Virus attachment to Vero cells using detection of vRNA by qRT-PCR as
a virion surrogate
It has been reported previously that DENV2 attachment to cell
receptors is non-saturable. These previous studies used
radioactively-labeled virus and LLC-MK2, Vero, C6/36, AP61, and
Huh-7 target cells (Hilgard and Stockert, 2000; Thaisomboonsuk
et al., 2005). Non-saturable binding kinetics may indicate non-
speciﬁc binding. We repeated the Vero cell attachment assay using
30P-NBX parental virus and qRT-PCR to detect bound/free vRNA.
Using this technique, we conﬁrmed the non-saturable kinetics of
DENV2 attachment to Vero cells using MOIs of 1, 10, or 100. In each
case, approximately 10% of input virus bound to cells regardless of
MOI (data not shown). Similarly, when the time course of attach-
ment was measured, the overall rate of attachment was similar
regardless of viral input (Fig. 4), further suggesting non-saturable
Fig. 4. Attachment curves of DENV2 30P-NBX to Vero cells at varying MOI.
Parental/wild type virus, 30P-NBX at indicated MOI was allowed to attach to Vero
cell monolayers at 4C and at indicated times cells were rinsed, harvested, and
attached DENV vRNA was measured by qRT-PCR. Panel A, MOI¼1; panel B,
MOI¼10; and panel C, MOI¼100.
Fig. 5. Competition for viral attachment to HepG2 cells with increasing concentra-
tions of heparin. Average percent reduction in viral attachment to HepG2 cells
measured by cell-associated vRNA (n¼3). Viruses: 30P-NBX (◊), KK122/123EE (□),
K122E (▲), KK291/295EV (X), KKK305/307/310EEE (■), E202K (●), and G304K (þ ,
dotted line). Standard error bars are shown.
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ment to cells we used a variety of techniques, e.g., treating cells
with trypsin or trypsin/RNase or trypsin/RNase/proteinase K post-
attachment to remove non-speciﬁcally bound virus and vRNA.
None of these techniques improved attachment speciﬁcity even if
protease treatment occurred after allowing time for internalization
(2 h incubation at 37C post-attachment, data not shown). Because
of these results, we did not to use attachment/qRT-PCR assay to
measure viral attachment.
Blocking viral attachment with heparin
Virus attachment to cells was further investigated in a heparin
inhibition experiment. As shown in Fig. 5, binding of w.t. 30P-NBXand mutant viruses to Hep-G2 cells could be inhibited up to 40% in
a dose-dependent manner by incubating with heparin. Only
KK122/123EE and K122E mutants were signiﬁcantly less suscep-
tible (po0.05, unpaired t-test) to heparin inhibition relative to wt
30 P-NBX virus at dose of 100 ug/ml (both mutants) or 1000 ug/ml
(onlyKK122/123EE).
Measuring negative (−) vRNA synthesis in virus-infected Vero cells as
an indication of virus replication in Vero cells
We previously measured virus attachment to Vero cells using
plaque assay (Crill and Roehrig, 2001). In that study, we used 100
plaque forming units (PFUs) in the attachment assay and by
counting plaques at 5 days p.i., we could calculate the percent
viral attachment that resulted in a viable infection, i.e., plaque
formation. We believe that this is the best system for performing
attachment assays; however, because many of our mutant viruses
were not able to grow in Vero cells, an assay that relied on viral
PFUs was not feasible.
Another method to determine the point at which entry-lethal
mutations block replication is to quantify production of (−) strand
vRNA post-attachment. The reasoning is that for (þ) vRNA viruses, if
a virus genome contains a lethal mutation that blocks initiation of (−)
vRNA synthesis, yet is fusion competent, the replication block must
occur prior to virion endocytosis, thus implying an early block in viral
entry, at least prior to fusion with endosomal membranes.
We performed these (−) vRNA synthesis studies by adsorbing
1104 TCID50 of DENV2 to Vero cells at 4C for 1 h, washing off
non-attached virus, and detecting initiation of replication by
measuring intracellular levels of (−) vRNA at 72 h post-
attachment (Fig. 6A). We compared levels of intracellular (−) vRNA
to viral growth by measuring extracellular (þ) vRNA at 4 and 72 h
post-attachment (Fig. 5B). Not surprisingly, Vero cells infected
with mutant viruses shown previously to be defective in mem-
brane fusion activity (Fig. 5A, mutants G104S, F108W, E133K, and
L135G) had no measurable intracellular (−) vRNA or viral growth.
The mutants that were fusion competent but failed to initiate (−)
vRNA synthesis in Vero cells were E202K, KK291/295EV, KKK305/
307/310EEE, VEPG382Δ, and VEPG382RGDK (Fig. 6A). Viral
Fig. 6. RT-qPCR quantitation of viral genomic equivalents for mutant DENV following a 1 h attachment to Vero cells at 4 1C. 1104 TCID50 mutant DENV2 was
adsorbed to Vero cells at 4C for 1 h, unattached virus was removed by washing. Five ml of extracted intracellular (−) vRNA) or extracellular (þ) vRNA) was quantitated using
qRT-PCR. Panel A: intracellular (−) vRNA measured at 72 h p.i. Panel B: extracellular (þ) vRNA measured at 4 h (black bars) and 72 h (white bars) p.i. Data are reported as
mean and standard error of the mean (n¼3).
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cells also showed little or no growth in these experiments as
determined by measuring extracellular levels of vRNA at 4 h and
72 h p.i. (Fig. 6B). As an additional control to this approach, we
measured levels of (−) vRNA in C6/36 cells infected with 30P-NBX
and the HS-binding/DIII mutants. All that were able to grow in
C6/36 cells expressed (−) vRNA at levels comparable to 30P-NBX
except for the triple mutant virus KKK305/307/310EEE. The level
of (−) vRNA in the triple mutant-infected C6/36 cells was about 10-
fold less (1105 vs. 1106 genomic copies) than the other
viruses, consistent with its reduced replication in C6/36 cells (data
not shown).
Infection of DC-SIGN transformed Raji cells
To analyze if the KKK305/307/310EEE or KK291/295EV viruses
could infect a mammalian cell line with a known alternative
attachment protein that did not rely on a heparan sulfate interac-
tion, we compared the ability of mutant viruses and wild-type
30P-NBX virus to infect Raji cells with and without DC-SIGN on the
surface. The Raji/0 cells are refractory to DENV, however Raji-DC-
SIGN cells can be infected. The interaction of DENV and DC-SIGN
has been shown previously to be mediated by the carbohydrate at
the N67 glycosylation site of the E-protein (Pokidysheva et al.,
2006). For these experiments we also included the fusion peptide
mutant G104S, shown previously to be defective in membrane
fusion, as a negative control virus. After a 1 h attachment at 4C, we
monitored viral growth by immunoﬂuorescence of infected cells
and qRT-PCR of progeny virus vRNA at 72 h p.i. By both methods
the 30P-NBX replicated only in Raji-DC-SIGN cells in a dose-
dependent manner (Fig. 7). None of the mutants infected either
Raji/0 or Raji-DC-SIGN cells.To determine if the introduced mutations had an effect on E
protein glycosylation, wild-type 30P-NBX, the two DIII mutants,
KKK305/307/310EEE and KK291/295EV, and the DII mutant, G104S,
mutants were concentrated from virus-infected cell culture med-
ium by anti-E protein afﬁnity chromatography with MAb 4G2, prior
to treating with either endoH or PNGase F Not surprisingly, the
resulting glycosidase treated virus E protein electrophoretic gel
proﬁles were identical for all four viruses, indicating two oligosac-
charide structures on the E-protein - one being an endoH suscep-
tible mannose glycan (presumably N67) and one site being an
endoH resistant complex glycan (N153) (data not shown). These
results are similar to results from other studies (Hacker et al., 2009)Discussion
The ﬂaviviral E protein mediates at least two crucial aspects of
infection—attachment and cell membrane fusion. We have identi-
ﬁed E protein AA sequence elements required for these critical
functions using mutant viruses obtained by transfection of C6/36
cells with DENV2 genome RNA transcribed from infectious cDNA
clones. Our previous studies identiﬁed the fusion peptide region
and the hinge region of the E protein as being critical for virus-
mediated membrane fusion in C6/36 cells and growth in Vero cells
(Butrapet et al., 2011; Huang et al., 2010). In this study we mutated
proposed surface accessible HS-binding motifs in DENV2 E protein
DI, II and III, including AAs in the lateral ridge of DIII-A strand, and
assessed the effects of these mutations on viral phenotype.
Two triple mutations, KKK122/123/128EEE and KRR284/286/
288EEE, were lethal in both C6/36 and Vero cells, so no progeny
viruses were obtained post-transfection, and these mutants were
not further studied. The KK291/295EE mutant was also unable to
Fig. 7. Growth of 30P-NBX and mutant viruses in Raji cells and DC-SIGN-transformed Raji cells. Viruses were attached to cells for 1 h at 4C, and unattached virus was
removed by rinsing in PBS. Four days p.i., cells were stained for expression of DENV2 antigens, and progeny virus genomes were quantitated by qRT-PCR. Panel A, IFA staining
of cells with DENV-2 polyclonal antibody; in order left to right: Raji-DC-SIGN cells infected with 30P-NBX (positive), Raji cells infected with 30P-NBX (negative), and light
microscopy of Raji/DC-SIGN cells to show cell density on slide. Change in genomic equivalents of 30P-NBX and mutant viruses from T¼0 to T¼72 h p.i. Raji/DC-SIGN cells (■)
and Raji/0 cells (□). A representative result is shown (n¼3).
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acquired (Table 2). While all other mutants, KK122/123EE, KK291/
295EV, KKK305/307/310EEE, E202K, and G304K, grew in C6/36
cells, their biology changed dramatically when grown in mamma-
lian Vero cells, where most mutations were lethal. Mutants K122/
123E, E202K, and G304K required compensatory modiﬁcations for
growth in Vero cells. All three of these modiﬁed viruses were
fusion competent in C6/36 cells in addition to growing in Vero
cells (Fig. 2).
The list of mutant viruses that retained viability suggested that
the highly DENV- and JEV-serogroup conserved K or R basic
residues at positions 282, 284, and/or 288 in the DI-HS-binding
cluster are essential for virus function in both C6/36 and Vero cells.
It should be noted that for HS cluster 1, structural analyses of the E
homodimer suggest that residues R188, H282, K284, R286, and
H288 are not readily accessible on the surface of the virion. The
buried location of most of these AAs might explain the overall AA
conservation of cluster 1 among ﬂaviviruses. The other highly
conserved residue in the DI-HS-binding cluster, K295, is also
critical and changing it to E295 resulted in lethality or instability
in both cell types. Both K291 and K295 are accessible on the virion
surface (Fig. 1). Substitution of the basic K295 to neutral V295 was
tolerated by C6/36 cells, but not by Vero cells. When comparing
the viability of viruses with the single, double and triple mutations
of K-E at the 122/123/128 residues in the DII-HS-binding cluster
(Table 2), it appears that the K128 (Table 1) is the most critical
determinant for viability in both cell types. On the other hand, the
K123E mutation mainly affected temperature sensitivity of the
virus at 37C (KK122/123EE was able to replicate in both C6/36 and
Vero cells at 28C). Another mutant, KK291/295EV, exhibited the
temperature sensitive phenotype at 37C in Vero cells, implying
that a charge change at positions 123, 291, and/or 295 may cause astructural instability of the E protein at 37C that might affect either
E protein intracellular processing or viral attachment.
Interestingly, the E202K and G304K mutations are not stable in
Vero cells, and compensatory mutations K122E and G330D, respec-
tively, evolved during virus replication. Both the E202 and K122, and
the G304 and G330 residue pairs are spatially close in the E protein
(Fig. 1), and the compensatory mutations would have reduced the
overall positive charges in the DII-HS-binding cluster or DIII A strand
to the same levels as the parental 30P-NBX virus. These results
suggest that the overall positive charges of these two clusters might
be critical for proper DENV2 infection in mammalian cells.
The K122E compensatory mutation that occurred during repli-
cation of E202K mutant in Vero cells has previously been observed
to evolve (K-E or I substitution) with other DENV2 E mutants
when grown in Vero cells (e.g., E133K, G266W, I270W, VEPGΔ, and
VEPG382RDGK) (Butrapet et al., 2011; Erb et al., 2010). Addition-
ally, the 16681 parental virus spontaneously accrued the K122E
mutation after multiple Vero cell passages (data not shown). These
observations suggest that change of the K122 in DENV2 to a non-
basic AA might represent a Vero cell-adaptation. We have also
found that the K122E adaptation greatly enhances the ability of
30P-NBX to infect Aedes aegypti mosquito midguts (Erb et al., in
preparation).
Two mutant viruses – KK291/295EV and KKK305/307/310EEE –
were lethal in Vero cells, but fusion competent in C6/36 cells
(Fig. 2). Because of this, we turned our attention to ascertaining
the replication block for these two viruses in Vero cells. Previous
attachment studies using radioactively-labeled virus demon-
strated that DENV attachment to a variety of cell types is non-
saturable (Hilgard and Stockert, 2000; Thaisomboonsuk et al.,
2005). We conﬁrmed those observations using qRT-PCR to detect
attached vRNA as a surrogate for virus. When virus attachment
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were generated (Fig. 4); however, the attachment curve kinetics,
and percent viral attachment (10%), did not change over a wide
range of MOIs, further suggesting non-saturable binding kinetics.
The inability to saturate viral binding sites on Vero cells is
perplexing. One explanation could be that non-speciﬁc binding is
high. Experiments designed to reduce non-speciﬁc binding failed
to do so. Regardless of this fact, not unexpectedly, attachment of
all viruses to mammalian cells could be reduced by previous
incubation of virus with heparin (Fig. 5). This competition was
seen in all viruses tested, likely because for each mutant, other HS-
binding sites were still present on the glycoprotein. Only KK122/
123EE and K122E became less susceptible to high dose of heparin
inhibition than the 30P-NBX virus, suggesting the basic residues at
122 and 123 might be a dominant cluster for HS binding.
Another perplexing observation is that it has been suggested
that DENV attachment is most efﬁcient at pH values below the
threshold necessary to catalyze the oligomeric reorganization of
the E homodimer to a fusion-competent E homotrimer (pH 5.5–
6.0) (Hilgard and Stockert, 2000; Thaisomboonsuk et al., 2005). It
is unclear how a virion with E proteins in a fusion-ready homo-
trimer would interact with the cell surface. Additionally, it has
been shown previously that when a ﬂavivirus is exposed to low
pH, it is inactivated (Guirakhoo et al., 1993). Because of these
observations, it is not clear what was being measured in low pH
attachment assays. Because most of our mutations resulted in
surface charge changes that could affect each mutant virus's
binding in different ways, we elected to conduct our attachment
assays at the physiological pH of 7.4.
Another factor that all previous binding studies have in
common is the failure to assess directly the ratios of prM/M in
virions. Virions with either uncleaved prM or with prM pre-
peptide still associated might have an altered attachment pheno-
type. Because our viral seeds were produced in C6/36 cells we
assume that all viruses have some prM on their surfaces, since it
has been observed that ﬂaviviruses produced from C6/36 cells
contain high proportions of prM (Randolph et al., 1990; Zhang
et al., 2003). Protein gel analysis of the KKK305/307/310 mutant
virus conﬁrmed the presence of prM in the virion (data not
shown).
Because of these caveats and our inability to establish a reliable
attachment assay, we used post-attachment synthesis of intracel-
lular (−) vRNA as a surrogate for viral attachment that leads to
infection. Mutant viruses that failed to produce (−) vRNA by 72 h
p.i. were G104S, L107M, F108W, E133K, L135G, E202K, KK291/
295EV, KKK305/307/310EEE, VEPG382Δ, and VEPG382RGDK
(Fig. 6A). Not surprisingly, we also found that these mutants did
not grow well in Vero cells at 72 h p.i. (Fig. 6B). Four of these
mutants, G104S, L107M, F108W, and L135G, were shown pre-
viously to be fusion-negative so these mutations are lethal for Vero
cells. Four other mutants, E133K, E202K, VEPG382Δ, and
VEPG382RGDK, required reversion or compensatory mutations
before they could grow in Vero cells. The growth of these four
mutants was readily observed at 12 days p.i. (Table 2 and Fig. 2), so
their failure to produce (−) vRNA by 72 h p.i. is probably associated
with the longer time necessary to accrue and select for the
rescuing mutations.
The KK291/295EV and KKK305/307/310EEE mutants were
fusion competent in C6/36 cells, but neither production of (−)
vRNA nor viral growth could be detected in Vero cells (Fig. 2A, and
Fig. 6B). Because these two mutations also resulted in loss of
reactivity with MAbs that have been shown to block attachment of
virus to Vero cells, it is likely that these viruses are not able to
attach to Vero cells (Crill and Roehrig, 2001). As discussed above,
the KK291/295EV mutant is temperature sensitive. Since our viral
attachment assays were performed at 4C, the inability of mutantKK291/295EV to attach to Vero cells is not related to E protein
conformational changes that might occur at 37C. Besides the MAbs
tested here, the epitope recognized by MAb 4E11, which strongly
neutralizes all DENV, has also been mapped to this region, AAs
304–314 (Thullier et al., 2001). Our analysis does not differentiate
loss of attachment caused by the loss of a HS-binding site from loss
of binding to a virus-speciﬁc receptor in DIII. Either or both
mechanisms could be in play here, because the conserved HS-
binding residues K305, K307, and K310 are located in DIII.
To evaluate attachment in another way, we tried to grow the
KK291/295EV and KKK305/307/310EEE viruses in Raji cells expres-
sing DC-SIGN on their surface. Previous studies have identiﬁed the
carbohydrate at the N67 of the E protein as the moiety involved in
DC-SIGN-mediated attachment. DENV infection of DC-SIGN-
bearing cells can be inhibited by chemicals that block acidiﬁcation
of endosomes (e.g., baﬁlomycin and chloroquine), suggesting that
DENV entry into these cells requires membrane fusion (Navarro-
Sanchez et al., 2003; Thullier et al., 2001). Because both the
KK291/295EV and KKK305/307/310EEE mutants have normal
fusion activity in C6/36 cells, we predicted that these mutants
would infect DC-SIGN-bearing mammalian cells, however neither
of these mutants nor an additional mutant, G104S (shown pre-
viously to be defective in cell membrane fusion) infected Raji-DC-
SIGN cells, despite w.t. virus glycosylation patterns. Interestingly,
the spread of DENV in infected Raji-DC-SIGN cells was less than
that seen in DENV-infected Vero cells, conﬁrming a previous study
(Navarro-Sanchez et al., 2003). These results suggest that there is
another, as yet undeﬁned attenuating step in DENV infection of
Raji-DC-SIGN cells.
Another alternative DENV entry mechanism is via Fc-receptors
on the cell surface after the virus is complexed with non-
neutralizing antibody. Additionally, it has recently been shown
that DENV can be labeled directly with ﬂuorescent dyes (Zhang
et al., 2010). These tagged viruses can be used to evaluate viral
attachment. We are currently using both approaches to expand
our understanding of the early events in DENV2 replication.Materials and methods
Site-directed mutagenesis, construction of infectious cDNA clones and
production of mutant viruses
Mutant genomic cDNAs of DENV2 were constructed using the
pD2/IC-30P-NBX plasmid (30P-NBX) containing full-length geno-
mic cDNA of DENV2, strain 16681, as previously described
(Butrapet et al., 2011; Erb et al., 2010; Huang et al., 2010). Mutant
viral RNA (vRNA) was transcribed in vitro from linearized full-
length cDNA, and the transcribed-RNA was transfected by electro-
poration of C6/36 or Vero cells. Working seed virus for each
mutant was obtained by one passage of the mutant virus in either
Vero or C6/36 cells. Full-length genome consensus sequencing of
viral seeds was performed to conﬁrm the ﬁnal genome sequence
of recovered mutants from each cell type.
Fifty percent tissue culture infectious dose (TCID50) assay
Virus infectivity titer was measured by TCID50 assay since some
of these mutants were unable to grow in Vero cells (Bryant et al.,
2007). Brieﬂy, C6/36 cells in 96-well tissue culture plates were
infected with serially diluted virus. Following incubation at 28C for
12 days, the plates were ﬁxed with acetone, and viral antigens
were detected by enzyme-linked immunosorbent assay (ELISA)
using DENV2—mouse hyperimmune ascitic ﬂuid (MHIAF). The
A405 nm was measured, and TCID50 titers were calculated using
the Reed–Muench method.
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Vero, K562, HepG2, and C6/36 cells were cultured as previously
described (Butrapet et al., 2011; Huang et al., 2010). Cell cultures in
75-cm2 ﬂasks were infected with mutant viruses in duplicate at a
multiplicity of infection (MOI) of 0.001 TCID50/cell. Vero cell
cultures were also used to test temperature sensitivity of the
mutants when replicated at 28C and 37C. Culture medium aliquots
were removed from each ﬂask every other day during 12 (for Vero)
or 14 days (C6/36) of culture incubation. Viral particles in the
medium were ﬁrst quantitated by measuring the genomic equiva-
lents (GE) of vRNA using one-step quantitative (q) RT-PCR. The
vRNA was extracted with QIAamp Viral RNA kit (Qiagen), and qRT-
PCR was conducted with iScrip one-step RT-PCR kit (BioRad) or
Quantitect virus kit (Qiagen) in the iCycler iQ5 (BioRad) with the
following protocol: 50C for 30 min and 95C for 15 min followed by
45 cycles of 95C for 15 s and 60C for 1 min. Primers/probe for the
qRT-PCR were universal DENV-10578 (AAGGACTAGAGGTTAGAG-
GAGACCC), universal CDEN-10687 (GGCGTTCTGTGCCTGGAATGATG),
and D24-10616 FAM probe (AACAGCATATTGACGCTGGGAAAGACC).
DENV vRNA fragments were in vitro transcribed from a DENV2 cDNA
subclone, quantitated by RiboGreen RNA quantiﬁcation kit (Molecular
Probe), and serially diluted to desired GE to generate the standard
curve for each one-step qRT-PCR assay. Only results for assays with
high standard curve PCR efﬁciency (95–105%) were accepted, and each
sample was measured in triplicate. After the growth curves plateaued
(as measured by qRT-PCR), samples were then tested for infectivity
titers by TCID50 assay to determine the peak infectious titers. Sequen-
cing of structural genes of viruses released into the medium was also
performed from the day 12 aliquot.
Epitope mapping of mutant viruses
MAb reactivity with the E proteins of each mutant was
performed by indirect ﬂuorescent antibody (IFA) assay (Gubler,
1987) using acetone-ﬁxed virus-infected C6/36 cells. A dilution
series of the following DENV2 MAbs (epitopes) was used to
determine reactivity end-points: DI, 1B4C-2 (C1); DII, 4G2 (A1),
6B6C-1 (A1), and 2H3 (A4); DIII, 3H5 (B1), 9A3D-8 (B2), and 1A1D-
2 (B4); and 2H2 (prM) (Roehrig et al., 1998). The MAb reactivity
with each mutant virus was compared to that with 30P-NBX
parental virus, and a four-fold or greater change in endpoint was
considered signiﬁcant.
E protein glycosylation. The glycosylation proﬁles of 30P-NBX
and the mutant DENV KKK305/307/310EEE, G104S, and KK291/
295EV were determined using previously published procedures
for endoglycosidase H (endoH) and PNGase F deglycosylation
(Bryant et al., 2007; Calvert et al., 2012). One modiﬁcation in this
protocol was made - using DENV EDII-reactive MAb 4G2 in the
antibody afﬁnity matrix to concentrate virus prior to glycosidase
treatment.
Fusion-from-within (FFWI) assay
FFWI of virus-infected C6/36 cells was assayed as previously
described (Butrapet et al., 2011; Huang et al., 2010). Percent cell
fusion induced by mutants versus 30PA-NBX parental virus was
calculated.
Virus attachment and growth measured by real time qRT-PCR
Generally, viral attachment and growth assays were performed
by ﬁrst allowing virus to attach at speciﬁc MOIs to Vero cells in 6-
well plates at 4C for 1 h, pH 7.4. For growth and RNA synthesis
analyses, after attachment and removal of unbound virus by
rinsing with ice cold PBS, maintenance medium was added, andthe plates were kept at 37C for 72 h. At 4 h post-attachment a
sample of medium was removed to determine residual virus. At
72 h p.i. a second sample of medium was removed to determine
the level of viral growth. At 72 h, total RNA was extracted from
cells with Trizol, and the amount of DENV negative (−) sense vRNA
was quantiﬁed as described below. Alternatively, viral attachment
curves for Vero cells were generated by harvesting cells from a 6-
well plate at 0, 5, 15, 30, 45, 60, and 90 min post-attachment at 4C,
rinsing cells to remove unbound virus, and quantifying cell-
associated vRNA using one-step qRT-PCR (as described above).
Five ml of both types of extracted RNAwere used to assess amounts
of both (−) vRNA and vRNA, and each time point was repeated in
triplicate.
Heparin inhibition. Heparin has been previously shown to
inhibit DENV infection of human liver cells lines (Lin et al.,
2002). In this study, we used HepG2 (human liver carcinoma) cell
line for the heparin inhibition tests. Heparin inhibition was tested
by pre-incubating a constant amount of virus (1108 GE) with
various concentrations (0, 0.1,1, 10, 100 and 1000 μg/ml) of soluble
heparin (H-3149, Sigma). The mixtures were incubated in binding
medium for 30 min at 4 1C, and then added to cells to determine
binding as described above.Quantitation of (−) vRNA
To detect RNA replication of mutants in Vero cells when a
mutation was shown to be lethal, we conducted a 2-step RTqPCR
procedure to quantitate DENV2 (−) vRNA using tagged primers as
previously described (Huang et al., 2010) to minimize false
ampliﬁcation of cDNA during RT (Peyreﬁtte et al., 2003). Brieﬂy,
DENV2 primers and probes selected for the assay were from the
3′-non-coding genome region (Houng et al., 2001). A 19-nt Tag
sequence (Peyreﬁtte et al., 2003) with no homology to DENV2
vRNA sequence was added to the 5′-end of the DENV2 primer,
T-D2-10551, used for RT. For RT, template RNAs were denatured at
65 1C for 5 min in the presence of 1 μM T-D2-10551 primer and
0.6 mM dNTP mix. After RT, the ampliﬁed cDNAwere quantiﬁed by
qPCR using the iQ™ Supermix kit (BioRad) with 0.4 μM primers
(Tag-primer containing only the 19-nt Tag and DENV2-speciﬁc
primer CD2-10703), and 2 μM DENV2 probe (D2-10656P). In vitro
transcribed (−) vRNA from a speciﬁcally-constructed plasmid
containing the primer/probe-target DENV2 cDNA fragment was
quantiﬁed and serially diluted to generate a standard curve for the
2-step RT-qPCR.Virus growth in Raji cells expressing DC-SIGN
DC-SIGN transformed- and untransformed-Raji cells [a human
B-cell lymphoma line (Epstein et al., 1966)] were gifts from Ted
Pierson (NIAID, USA), and were used to assess viral growth in
mammalian cells that express an alternative DENV receptor
protein for which the virus binding motif is known. The expression
of DC-SIGN was monitored by IFA with the DC-SIGN/DC-SIGNR
reactive MAb, 1621 (R&D Systems, Minneapolis, MN). Parental
30P-NBX and mutant viruses (KKK305/307/309EEE, KK291/295EV,
and G104S) were incubated with 1106 cells of either type for 1 h
at 4C, at various MOI. After absorption, nonattached virus was
removed by rinsing in PBS. Virus-infected cells were then incu-
bated for 3 days, and virus growth was measured by either
detecting the expression of cell-associated E protein by IFA using
a mouse hyperimmune ascitic ﬂuid to DENV2, or qRT-PCR for
progeny vRNA (see above). The mutants were evaluated in the
same manner.
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Most results are reported as mean7standard deviation from
3 or 4 separate experiments. Student's t test was used to test for
signiﬁcance, and results that had p values o0.05 were considered
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